B-lymphocyte depletion with rituximab and β-cell function: Two-year results

Diabetes Care

Volumn 37, Issue 2, 2014, Pages 453-459

  Pescovitz, Mark D ^a   Greenbaum, Carla J ^b   Bundy, Brian ^c   Becker, Dorothy J ^d   Gitelman, Stephen E ^e   Goland, Robin ^f   Gottlieb, Peter A ^g   Marks, Jennifer B ^h   Moran, Antoinette ⁱ   Raskin, Philip ^j   Rodriguez, Henry ^a,c   Schatz, Desmond A ^k   Wherrett, Diane K ^l   Wilson, Darrell M ^m   Krischer, Jeffrey P ^c   Skyler, Jay S ^h  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BENAROYA RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Och Spine at New York Presbyterian Hospitals   (United States)

^g UNIVERSITY OF COLORADO DENVER   (United States)

^h UNIVERSITY OF MIAMI   (United States)

ⁱ UNIVERSITY OF MINNESOTA   (United States)

^j UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^k UNIVERSITY OF FLORIDA   (United States)

^l HOSPITAL FOR SICK CHILDREN   (Canada)

^m STANFORD UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; PLACEBO; RITUXIMAB;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; B LYMPHOCYTE; CHILD; CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS, TYPE 1; FEMALE; HUMAN; IMMUNOLOGY; LYMPHOCYTE DEPLETION; MALE; PANCREAS ISLET; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AREA UNDER CURVE; B-LYMPHOCYTES; CHILD; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; ISLETS OF LANGERHANS; LYMPHOCYTE DEPLETION; MALE; PLACEBOS; YOUNG ADULT;

EID: 84893118586     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-0626     Document Type: Article

References (18)

1. The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. Ann Intern Med 1998;128:517-523
2. Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003;26:832-836
3. Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in newonset type 1 diabetes mellitus. N Engl J Med 2002;346:1692-1698
4. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3- antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005;352:2598- 2608
5. Orban T, Bundy B, Becker DJ, et al.; Type 1 Diabetes TrialNet Abatacept Study Group. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 2011;378: 412-419
6. Mariño E, Silveira PA, Stolp J, Grey ST. B celldirected therapies in type 1 diabetes. Trends Immunol 2011;32:287-294
7. Pescovitz MD. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transplant 2006;6:859-866
8. Pescovitz MD, Greenbaum CJ, Krause- Steinrauf H, et al.; Type 1 Diabetes TrialNet Anti-CD20 Study Group. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009; 361:2143-2152
9. Herold KC, Gitelman S, Greenbaum C, et al.; Immune Tolerance Network ITN007AI Study Group. Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin Immunol 2009;132:166-173
10. Keymeulen B, Walter M, Mathieu C, et al. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 2010;53:614- 623
11. Orban T, Bundy B, Becker DJ, et al.; Type 1 Diabetes TrialNet Abatacept Study Group. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up one year after cessation of treatment. Diabetes Care. 2 December 2013 [Epub ahead of print]
12. Cambridge G, Leandro MJ, Edwards JC, et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 2003;48:2146-2154
13. Hauser SL, Waubant E, Arnold DL, et al.; HERMES Trial Group. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358: 676-688
14. Pescovitz MD, Torgerson TR, Ochs HD, et al.; Type 1 Diabetes TrialNet Study Group. Effect of rituximab on human in vivo antibody immune responses. J Allergy Clin Immunol 2011;128:1295-1302, e5
15. Castillo J, Milani C, Mendez-Allwood D. Ofatumumab, a second-generation anti- CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders. Expert Opin Investig Drugs 2009;18:491-500
16. Morschhauser F, Leonard JP, Fayad L, et al. Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non- Hodgkin's lymphoma: phase I/II results. J Clin Oncol 2009;27:3346-3353
17. Cardarelli PM, Rao-Naik C, Chen S, et al. A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies. Cancer Immunol Immunother 2010;59: 257-265
18. Peter HH, Warnatz K. Molecules involved in T-B co-stimulation and B cell homeostasis: possible targets for an immunological intervention in autoimmunity. Expert Opin Biol Ther 2005;5(Suppl. 1):S61-S71